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Abstract
Background: Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma
(HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as
possible candidate biomarkers for prediction of HCC was performed using soluble Fas (sFas), soluble tumor
necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).
Results: The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease
associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with
persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for
hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their
serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when
compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and
significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having
PNALT could be predicted with 90% sensitivity and 70.6% specificity when sTNFR-II is ≥ 389 pg/ml or IL-8 is < 290
pg/ml.
Conclusions: Serum TNFR-II, IL-2Ra and IL-8, may be used as combined markers in HCV-infected cases for patients
at high risk of developing HCC; further studies, however, are mandatory to check these findings before their
application at the population level.
Background
Hepatocellular carcinoma (HCC) ranks as the fifth most
common cancer around the world and the third most fre-
quent cause of cancer-related death. It represents the most
common primary malignant tumor of the liver and is one
of the major causes of death among patients with cirrhosis
[1]. The increased incidence of HCC in the United States
as well as in Japan over the past 20 to 30 years [2,3] has
been partially attributed to the emergence of the hepatitis
C virus (HCV), an established risk factor for developing
HCC [4,5]. The prevalence of HCV infection varies signifi-
cantly; higher rates have been reported in African and
Asian countries, whereas industrialized nations in North
America, northern and western Europe, and Australia had
lower prevalence rates [6]. Egypt has the highest preva-
lence of HCV in the world, ranging from 6 to 28% [7-10],
with an average of approximately 13.8% in the general
population and there is an expected increase in hepatitis
C-related mortality in that country [11].
The continued viral replication and persistent attempt
by a less than optimal immune response to eliminate
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tions, accumulation of chromosomal damage and possi-
bly initiation of hepatic carcinogenesis [12]. The
prognosis of HCC is generally most serious with a great
need for serum markers that could be used for its early
detection and, consequently, to start a therapeutical pro-
cedure as soon as possible, potentially at a curable
phase. Serum a-fetoprotein (AFP) levels are frequently
not elevated at a significant proportion in patients with
early-stage, potentially curable, HCC. Therefore, other
markers should have been studied in an attempt to
identify a more sensitive laboratory test.
Cytokines are small secreted proteins which regulate
immunity, inflammation and haematopoiesis in connec-
tion with liver disease progression due to chronic HCV
infection, which is associated with an imbalance between
pro- and anti-inflammatory cytokines. Therefore, ele-
vated serum cytokines could be a risk factor for the
occurrence of HCC in patients with HCV related
chronic hepatitis and cirrhosis. Cytokines were shown to
be used as biomarkers for early detection of HCC [13]
in addition to their possible use as potential predictors
for interferon (IFN) treatment in HCV genotype-4
patients [14]. Several cytokines are involved in the pro-
cess of HCC invasion and metastasis, including soluble
Fas (sFas), soluble tumor necrosis factor receptor-II
(sTNFR-II), interleukin-2 receptor (IL-2R) and interleu-
kin-8 (IL-8). As the knowledge of tumor biology
becomes progressively clear, more and more new bio-
markers with high sensitivity and specificity could be
found and then routinely used for clinical assays.
The sFas, obviously increased in HCC with a signifi-
cant difference between patients of chronic liver disease
(CLD) and normal controls, was found to correlate with
the severity of liver disease and to resist the occurrence
of HCC apoptosis [15,16]. In chronic hepatitis B virus
(HBV) or HCV infected patients, serum IL-2R was used
both to screen high-risk patients and to monitor treat-
ment responses in patients with hepatitis who develop
HCC. Serum IL-2R appeared not only with a signifi-
cantly greater frequency than AFP, but was a more sen-
sitive marker of successful treatment and recurrence of
HCC as well [17].
Circulating TNF-a level increases during HBV [18-22]
and HCV infection [18,23-26] and is correlated with the
severity of hepatic inflammation, fibrosis and tissue
injury [18,22,24,27]. TNF-a plays a role in initiating
fibrogenesis through binding to specific cellular recep-
tors; i.e., TNFRs [28], which can be proteolytically
cleaved into two soluble forms: sTNFR-I and sTNFR-II.
High concentration of sTNFR-II has been observed for
prolonged periods in the circulation of patients with
various inflammatory diseases (including HCV infec-
tion), making sTNFR-II an ideal serum biomarker for
characterizing type 1 immune response [29-32]. More-
over, IL-8 contributes to human cancer progression
through potential mitogenic, and angiogenic functions.
IL-8 expressions plays a more critical role in the meta-
static potential of human HCC (such as vascular inva-
sion) than in angiogenesis or tumor proliferation [33].
Our aim was to evaluate the serum levels of sFas,
TNFR-II, IL-2R and IL-8 as possible candidate biomar-
kers for an early detection of HCC.
Results
The clinical characteristics of the studied groups are
shown in Table 1. All recruited patients were positive
for HCV antibodies, PCR for HCV RNA and all had
genotype-4. Mean age of patients with HCC was signifi-
cantly higher than that of the other groups (p < 0.001).
Liver function tests were significantly elevated, whereas
log-HCV titer was significantly lower in HCC patients
(p < 0.001) when compared to patients with chronic
hepatitis C with persistent normal alanine aminotrans-
ferase levels (PNALT) and chronic liver disease (CLD)
patients. Figure 1 shows the distribution of log-HCV
titer in the different study groups, which included 68
men and 29 women. Mann-Whitney test was used for
comparing log-HCV, sFas, sTNFR-II, sIL-2R and IL-8
values with gender. Comparing the means of men versus
women, the former had only higher and significant (p =
0.04) log-HCV titer (11.16 ± 4.1) and (9.7 ± 1.5), respec-
tively; however, all other markers did not statistically
differ.
Table 2 depicts the comparison of the serum levels of
sFas, sTNFR-II, sIL-2Ra and IL-8. HCC patients had
higher sFas, sTNFR-II and sIL-2R than patients with
PNALT, CLD and normal controls with a significant dif-
ference for sFas between HCC patients and control (p <
0.001). The sTNFR-II was significantly elevated in HCC
patients compared to those with PNALT and CLD (p <
0.001), whereas sIL-2R was significantly elevated in
HCC patients when compared to those with PNALT
Table 1 Patients characteristics and log-HCV titer among
the different study groups
Variables Control
(9)
PNALT
(17)
CLD (32) HCC (30) p-value
M/W 7/2 12/5 24/8 25/5 < 0.001
Age (years):
Mean ± SD
50.9 ± 4.6
b 35.1 ±
11.5
c
43.4 ± 8.7
b 60.7 ± 8.3
a < 0.001
Log HCV-titer <615* 10.9 ± 3.2
a 9.9 ± 4.1
a 5.2 ± 4.7
b < 0.001
Groups with similar letters are not different statistically. A p-value < 0.05 was
considered significant. M/W: Men/Women; PNALT: chronic hepatitis C with
persistent normal alanine aminotrasferase; CLD: chronic liver disease; HCC:
hepatocellular carcinoma. *All cases were under detection limit (<615 IU/ml)
and so they were not included in the statistical analysis (Kruskal-Wallis
ANOVA).
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nificantly lower among HCC patients when compared to
the other groups (p < 0.001); but with no significance
between the other groups. The scatter diagrams of the
studied cytokines in the different study groups are
shown in Figures 2, 3, 4 and 5.
Correlation was done between the serum levels of the
studied cytokines, liver enzymes and log-HCV titer. The
liver enzymes, aspartate aminotransaminase (AST), ala-
nine aminotransferase (ALT), and alkaline phosphatase,
were significantly correlated with sTNFR-II, sIL-2R and
IL-8, as exhibited in Table 3.
A statistically significant correlation was found
between log-HCV RNA, sTNFR-II and IL-8 (p =0 . 0 6
and 0.000) respectively, whereas sIL-2R and sFas did not
show any significant difference in relation to log-HCV
titer.
Moreover, correlation studies revealed a significant
correlation between sFas, in the one hand, and sTNFR-
II or IL-2R, in the other hand (p = 0.01 and 0.000,
Study groups
0.0
3.0
6.0
9.0
12.0
15.0
P
C
R
 
l
o
g
 
v
a
l
u
e
s
CLD                                     HCC PNALT                            
Figure 1 Scatter diagram of the distribution of log-HCV titer results among the different study groups. PNALT: Chronic hepatitis C with
persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
Table 2 Serum levels of sFas, sTNFR-II, sIL-2R and IL-8 in the different study groups.
Cytokines
(pg/ml)
Control PNALT CLD HCC p-value
sFas 316 ± 62.5
b 605.82 ± 304
ab 814.94 ± 362
a 762.18 ± 437
a < 0.001
sTNF-RII 375.26 ± 58.4
ab 268.58 ± 129
b 315.27 ± 133.5
b 480.16 ± 154.4
a < 0.001
sIL-2Ra 639.84 ± 78.7
b 710.10 ± 422
b 845.38 ± 385.2
ab 1372.58 ± 779.6
a 0.001
IL-8 345.84 ± 75.6
a 350.7 ± 53.6
a 352.33 ± 98.3
a 228.61 ± 51.1
b < 0.001
Values are expressed as mean ± SD. Groups with similar letters are not statistically different. A p-value < 0.05 was considered significant; PNALT: chronic hepatitis
C with persistent normal alanine aminotrasferase; CLD: chronic liver disease; HCC: hepatocellular carcinoma.
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Figure 2 Scatter diagram representing the distribution values of sFas in the different study groups. NC: normal controls; PNALT: Chronic
hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
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Figure 3 Scatter diagram representing the distribution values of sTNFR-II in the different study groups. NC: normal controls; PNALT:
Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
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Figure 4 Scatter diagram representing the distribution values of sIL-2Ra in the different study groups. NC: normal controls; PNALT:
Chronic hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
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Figure 5 Scatter diagram representing the distribution values of IL-8 in the different study groups. NC: normal controls; PNALT: Chronic
hepatitis C with persistent normal alanine aminotrasferase; CLD: Chronic liver disease; HCC: hepatocellular carcinoma.
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nificantly correlated with sFas, IL-2R or IL-8 (p = 0.01,
0.000 and 0.004, respectively). IL-2R was significantly
correlated with either sFas or IL-8 (p = 0.000 and 0.02,
respectively). IL-8 was negatively correlated with
sTNFR-II or IL-2R (p = 0.000 and 0.02, respectively).
In the present study, levels of AFP among HCC
patients were ≥ 200 ng/ml in 9 patients, whereas 11
patients had levels < 200 ng/ml. There was no statisti-
cally significant difference when the levels of AFP were
assessed against the serum levels of any of the studied
cytokines.
Receiving operating characteristic (ROC) analysis
curves and the corresponding area under the curve were
calculated for providing the accuracy of the cytokines in
differentiating between the different groups under con-
sideration. Sensitivity (i.e., true positive rate), specificity
(i.e., true negative rate), positive predictive value, nega-
tive predictive value and cutoff values showing the best
equilibrium between sensitivity and specificity were eval-
uated. ROC curve and best cutoff values were calculated
for patients with PNALT and HCC because there was
no good discrimination between the other groups. ROC
curve values for sTNFR-II and IL-8 among PNALT and
HCC patients yielded a cutoff of 398 pg/ml and 345 pg/
ml, respectively, as shown in Table 4, and Figures 6 and
7. ROC curve for IL-2R and sFas is shown in Figure 6.
Further analyses on the cytokines in HCC and PNALT
patients are shown in Table 5. Only sTNFR-II and IL-8
levels among patients with PNALT and HCC were ana-
lyzed. There were no satisfactory cutoff values for either
IL-2R or sFas for both specificity and sensitivity, i.e., one
on the expense of the other as evident by the ROC curve.
Among the HCC patients, 22/30 (73.3%) had mean
sTNFR-II levels of ≥ 398 pg/ml, whereas only 2/17
(11.8%) cases with PNALT had this value with a highly
significant difference (p = 0.000). Regarding IL-8, 29/30
(96.7%) HCC patients had IL-8 level < 345 pg/ml com-
pared to only 4/17 cases with PNALT, whereas most
PNALT patients had IL-8 ≥ 345 pg/ml (p =0 . 0 0 0 ) .
When both sTNFR-II and IL-8 were combined together,
all HCC cases 100% had either sTNFR-II ≥ 398 pg/ml
or IL-8 < 290 pg/ml (p = 0.000) and 21/30 (70%) HCC
had sTNFR-II ≥ 398 pg/ml and IL-8 < 290 pg/ml com-
pared to none of PNALT cases (p = 0.000). In this vein,
combined assessment of both sTNFR-II and IL-8 at a
cutoff of ≥ 398 pg/ml and < 290 pg/ml, respectively,
would be better in the diagnosis of HCC than either of
them individually.
Discussion
HCC generally develops following an orderly progres-
sion from cirrhosis to dysplastic nodules to early cancer
development, which can be reliably cured if discovered
before the development of vascular invasion [34]. Early
detection of HCC in those patients provides the best
Table 4 ROC curve values for sTNFR-II and IL-8 in PNALT
and HCC patients
ROC values sTNF-RII ≥ 398 IL-8 ≥ 345 TNFR-II ≥ 398
or IL-8 <290
Sensitivity 73.3% 96.7% 100%
Specificity 88.2% 76.5% 70.6%
AUC 0.849 0.588 0.794
NPV 65.2% 92.2% 100%
PPV 91.7% 87.9% 85.7%
ROC - receiving operating characteristic; AUC - area under the curve; NPV -
negative predictive value; PPV - positive predictive value; PNALT: Chronic
hepatitis C with persistent normal alanine aminotrasferase. HCC:
hepatocellular carcinoma.
Table 3 Correlation of different markers, liver enzymes showing Pearson’s r value and p-values
Labs ALT ALP log-HCV titer sFas sTNFR-II IL-2R IL-8
AST 0.55
(0.000)
0.497
(0.000)
-0.481
(0.000)
0.127
(0.3)
0.265
(0.029)
0.332
(0.006)
-0.415
(0.000)
ALT 0.590
(0.000)
0.027
(0.828)
0.338
(0.002)
0.253
(0.021)
0.392
(0.000)
-0.269
(0.014)
ALP -0.218
(0.083)
0.081
(0.5)
0.342
(0.004)
0.374
(0.002)
-0.488
(0.000)
log-HCV titer 0.006
(0.96)
-0.220
(0.067)
-0.170
(0.15)
0.488
(0.000)
sFas 0.276
(0.010)
0.403
(0.000)
-0.139
(0.199)
sTNFR-II 0.598
(0.000)
-0.304
(0.004)
IL-2R -0.236
(0.028)
Correlation is significant at the level of a < 0.05. The p-value appears within brackets. AST - aspartate aminotransaminase; ALT - alanine aminotransferase; ALP -
alkaline phosphatase.
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Page 6 of 12chance for a curative treatment, but AFP levels are fre-
quently normal in patients with small HCC and are not
elevated in a significant proportion of patients with
early-stage, potentially curable HCC.
Elevated concentrations of cytokines represent a char-
acteristic feature of CLD, regardless of the underlying
etiology, and may represent a consequence of liver dys-
function instead of an inflammatory disorder [35]. Cyto-
kines imbalance between T-helper 1 (Th1) and T-helper
2 (Th2) can prolong inflammation, leading to necrosis,
fibrosis and CLD [36] in addition to the development
and progression of HCC [37]. Cytokine production is
thought to play an important role in the recruitment of
tumor associated inflammatory cells, induction of angio-
genesis and direct modulation of tumor cell proliferation
[38,39]. The cytokines studied in this work were care-
fully chosen to include cytokines of the Th1 repertoire
(IL-2R and sTNFR-II), in addition to one of the impor-
tant pro-inflammatory cytokines (IL-8), and other fac-
tors as sFas.
In the present study, liver function tests were signifi-
cantly elevated whereas log-HCV titer was significantly
lower in HCC patients (p < 0.001) when compared to
PNALT and CLD patients. In agreement with our find-
ings, HCC group had the highest values (86.3%) for var-
ious concurrently-measured liver function tests,
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Figure 6 ROC (Receiving operating characteristic) curve showing sFas, sTNFR-II and IL-2Ra in PNALT. Chronic hepatitis C with persistent
normal alanine aminotrasferase) versus HCC (hepatocellular carcinoma) patients.
Figure 7 ROC (Receiving operating characteristic) curve
showing IL-8 in PNALT (chronic hepatitis C with persistent
normal alanine aminotrasferase) versus HCC (hepatocellular
carcinoma) patients.
Table 5 sTNFR-II and IL-8 levels in PNALT and HCC cases
Cytokines (pg/
ml)
PNALT, N = 17 HCC, N = 30 p-value
sTNFR-II ≥ 398 2 (11.8%) 22 (73%) 0.000
sTNFR-II < 398 15 (88.2%) 6 (27%) 0.000
IL-8 < 345 4 (23.5%) 29 (97%) 0.000
IL-8 ≥ 345 13 (76.5%) 1 (3.3%) 0.000
TNFR-II ≥ 398 or
IL-8 <290. Either
+v e
5 (29.4%) 30 (100%) 0.000
TNFR-II ≥ 398
and IL-8 <290.
Both - ve
12 (70.6%) 0 (0%) 0.000
TNFR-II ≥ 398
and IL-8 <290.
Both + ve
0 (0%) 21 (70%) 0.000
Others 17 (100%) 9 (30%) 0.000
PNALT: chronic hepatitis C with persistent normal alanine aminotrasferase;
HCC: hepatocellular carcinoma.
Zekri et al. Comparative Hepatology 2010, 9:1
http://www.comparative-hepatology.com/content/9/1/1
Page 7 of 12significant higher values of AST/ALT, ALT, AST (each,
p < 0.001) than cirrhotic patients as previously reported
[40]. On the other hand, HCV levels were markedly
higher in non-cancerous liver than in HCC (p =0 . 0 0 1 )
[41]. Moreover, comparing HCV titers of four HCC iso-
lates and surrounding cirrhotic liver tissues in two anti-
H C Vp o s i t i v ep a t i e n t s ;t h ec o p yn u m b e r so fH C V - R N A
were 1 × 10
6 and 4 × 10
6/gm wet weight of HCC, and 8
×1 0
7 and 3.2 × 10
8/gm wet weight of cirrhotic liver tis-
sues from patient-1 and -2, respectively [42]. The pre-
sent study showed that men had higher log-HCV RNA
titer than that detected in women; then, a strong evi-
dence is provided in favour of a higher HCV clearance
rate in women compared with that in men [43].
Fas (APO-1 or CD95) is a cell-surface receptor that
transduces apoptotic signals from Fas ligand (Fas-L)
[44]. Apoptosis is tightly regulated throughout a variety
of mechanisms, one of which is postulated to be the
production of soluble forms of Fas (sFas) that normally
binds to Fas-L, thus blocking the signaling of the mem-
brane-bound form of Fas. Peripheral blood mononuclear
cells in HCV infection exhibit decreased susceptibility to
Fas-L induced cell death. This may signify a mean by
which HCV escapes immune surveillance; however, it
would be worth a further investigation on this phenom-
enon. The sFas appeared to increase in advanced stages
of HCV-induced liver disease, as a result of host-related
immunological factors [45]. In the present series, the
mean values of sFas were significantly higher in HCC
patients compared to the other groups (p <0 . 0 0 1 ) .T h i s
could be explained by the role of sFas in the inhibition
of apoptosis, progression to end stage liver damage, and
subsequent development of HCC. Similarly, a significant
elevation of serum levels of sFas in HCC patients com-
pared with liver cirrhosis and healthy control was pre-
viously reported [46]. Previous studies [47,48] have
reported mRNA encoding secreted sFas in a number of
hepatitis and HCC cases indicating that sFas may func-
tion as an inhibitor of the Fas/Fas-L system and escape
of tumor cells from immune surveillance may then
occur. In chronic hepatitis, sFas was correlated with the
severity of disease [15] and its expression can illustrate
the mechanism of liver injury caused by death receptors
throughout the multistep process of fibrosis/carcinogen-
esis. So, the increased incidence of HCC is correlated
not only with the higher degree of hepatic fibrosis, but
also with the lower expression of Fas protein [49].
The rate of progression to end-stage liver disease
might be related to an up-regulation of the TNF-a/Fas
pathways and an age-dependent host response [50]. Pro-
inflammatory TNF-a released by host and tumor cells is
an important factor involved in initiation, proliferation,
angiogenesis as well as metastasis of various cancer
types [51]. Activities of TNF-a are mediated through
TNFR-I and TNFR-II [52]. Our results showed that
levels of sTNFR-II were elevated in patients with
PNALT, CLD and HCC with a significant difference
between HCC in relation to the other two groups (p <
0.001). These results are in agreement with previous
published results [13,29,53], where it was found that
sTNFR-IIa were closely correlated with disease progres-
sion in chronic HCV infection. Enhanced TNF-a and
TNFRs in chronic HCV infection may reflect the histo-
logical activity of the disease and TNFRs up-regulation
might modify host response and potentially contribute
to liver damage [54].
IL-2 is a cytokine produced by T cells in response to
inflammatory stimuli. It induces the surface expression
of IL-2 receptor (IL-2R) and, consequently, the produc-
tion of its soluble form, sIL-2R. The excess of sIL-2R is
capable of binding IL-2 and causes the inhibition of an
appropriate immune response. IL-2R is the protein that
mediates the action of IL-2, which is normally not dis-
played at a significant number on T and B cell surfaces.
Stimulation of the immune system causes two IL-2R
changes: more molecules of “IL-2R” expressed on the
cell plasma membrane and sIL-2Ra is released by the
activated cells into the surrounding fluid [55]. Our
results showed that levels of IL-2Ra were elevated in all
studied patients with a statistically significant difference
in HCC patients when compared to those with PNALT
(p = 0.001). This could be attributed to the binding of
IL-2 due to excess of its receptor and thus inducing an
inhibition of the appropriate immune response with
subsequent progression of chronic liver disease and the
development of HCC. Previous results [13,17,56] are in
agreement with ours, where it is was shown that serum
levels of sIL-2R are correlated with the histological
severity of liver damage in HCV patients, which may be
used as a marker in patients at high risk of getting HCC
as the highest levels of soluble IL-2R occurred in those
patients. The sIL-2R may be an important marker for
assessing the phase of active chronic hepatitis and the
degree of liver damage [57]. High sIL-2R levels, found in
patients with chronic HBV [58,59], were related to the
activity of the disease rather than to the virus replica-
tion; thus, those levels may be a useful marker of T-cells
immune response. In contrast to our results, it was con-
cluded that IL-2R was not detectable in HCC patients in
comparison to patients with chronic hepatitis and liver
cirrhosis [60]. Regarding the levels of IL-2R in patients
with HCC, and in agreement with our findings, there
was no statistically significant difference (p =0 . 6 2 )
between its values in men and women [55].
IL-8 is a chemoattractant cytokine which is produced
after stimulation with numerous exogenous and endo-
genous agents. Viruses induce IL-8 production leading
to enhanced viral RNA replication and cytopathic
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tion of that interleukin was able to attenuate the IFN-a
mediated inhibition of viral replication [61]. In the cur-
rent study, levels of IL-8 were significantly lower in
HCC patients than in the other groups (p <0 . 0 0 1 ) .O n
the contrary, other results found that serum IL-8 levels
were markedly elevated in most HCC patients compared
with healthy subjects [62] and was found to be over
expressed in the HCC tumor cells compared with the
non-tumorous livers [63]. Furthermore, multivariate
analyses revealed that the levels of the interleukin under
consideration may play an important role in the pro-
gression and dissemination of HCC and is an indepen-
dent predictor of long-term survival among those
patients. High-serum level of that cytokine may reflect
active angiogenesis and rapid tumor growth in HCC.
Therefore, targeting IL-8 can represent a potential
approach to control angiogenesis and invasion of HCC
[62]. In agreement with our results, there was no signifi-
cant correlation between serum concentration of that
cytokine and patient gender (p = 0.215) [63].
The present series showed that HCV viral load was
significantly correlated with sTNFR-II and IL-8. The
production of the latter was found to enhance viral
RNA replication [61], thus the low levels of the interleu-
kin in our HCC patients are in accordance with the low
HCV viral load. Moreover, there is a good correlation
between reduction in virusl o a da n dI L - 8l e v e lw h i c h
may indicate that it is related to viral infection rather
than to hepatocarcinogenesis.
In the current series, the studied cytokines were sig-
nificantly correlated to each other. The sFAS was posi-
tively correlated with sTNFR-II and IL-2R; sTNFR-II
positively correlated with IL-2R and negatively with IL-
8; lastly IL-2R and IL-8 were negatively correlated.
Th1 cytokines, which include IL-2R and sTNFR-II, are
in favor of an effective immune response against viral
infection, whereas Th2 (represented by IL-8 in our
study), is in favor of progressive inflammation, continu-
ous cell injury and persistent HCV infection [64].
The depicted correlations could highlight the imbal-
ance between pro- and anti-inflammatory cytokines
among patients with CLD and HCC. Furthermore, the
rate of progression of CHC to end-stage liver disease
might be related to an up-regulation of the TNF-a/Fas
pathways [50].
Analysis of sTNFR-II and IL-8 by ROC curves
revealed satisfactory values regarding sensitivity and spe-
cificity at a cutoff value of ≥ 398 pg/ml and ≤ 290 pg/
ml, respectively, when both markers were combined.
Therefore, a simultaneous assessment of both sTNFR-II
and IL-8 would be beneficial for the diagnosis of HCC;
in fact, they were capable of differentiating between
patients with PNALT and HCC – hence, an early
detection of HCC among apparently healthy patients
with PNALT levels. Nonetheless, these values must be
evaluated on a larger scale of patients with various
stages of CLD and HCC, in order to be used as new
markers for an early detection of HCC.
Conclusions
Cytokines are involved during disease progression in
HCV-infected patients. Early detection of HCC patients
is essential in the course of HCV associated CLD and its
sequels. IL-2Ra, TNFR-II and sFas were significantly
higher, whereas IL-8 values were significantly lower in
HCC patients in comparison to the other groups. Our
preliminary data revealed that exclusion of HCC among
PNALT patients could be predicted when both sTNFR-
II and IL-8 are assessed together at a cutoff value ≥ 389
pg/ml and IL-8 < 290 pg/ml, respectively. Nevertheless,
further studies with a largers a m p l es i z ea r em a n d a t o r y
to underline the accuracy of our findings before their
application at the population level.
Methods
Study population
Peripheral blood samples from 79 adult patients with
HCV related CLD (with or without HCC) and from 9
healthy subjects (served as the control group) were col-
lected, between April 2005 and June 2006, in the specia-
lized liver clinic of the National Cancer Institute (NCI),
Faculty of Medicine, Cairo University, before receiving
any treatment. All samples were analyzed for cytokine
quantitation. The study was approved by the Investiga-
tion and Ethics Committee of the hospital and a written
consent was obtained from all the persons involved.
The group size included 30 patients with HCC besides
CLD diagnosed by abdominal ultrasonography, triphasic
CT abdomen, serum AFP and confirmed histomorpho-
logically; 32 patients with CHC with elevated ALT
levels; 15 patients with fibrosis stage ranged from F1-F4;
7 patients with histopathological evidence of cirrhosis
(F5-F6); 17 patients patients with PNALT levels for at
least 6 months, no organomegaly on ultrasonographic
examination and fibrosis stage less than F2, i.e., mild
fibrosis.
The nine above mentioned healthy subjects (control
group) were 50.9 years old (mean) ± 4.6 (standard devia-
tion), with male/female ratio of 7/2, with no clinical or
biochemical evidence of liver disease or known medical
illness at recruitment and with normal abdominal ultra-
sonography. All controls were negative for HBV and
HCV as evidenced by negative serological markers and
negative PCR for HBV and HCV.
Exclusion criteria were: patients with HBV, history of
drug hepatotoxicity, autoimmune liver disease and meta-
bolic liver diseases.
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A detailed history, clinical assessment, biochemical liver
profile, abdominal ultrasonography were done to all
study groups in addition to serologic testing, virological
assay by quantitative PCR (VERSANT HCV RNA 3.0
Assay), HCV genotyping using INNO-LiPA III provided
by Innogenetics [65] and histolopathological examina-
tion among CLD disease patients to determine the his-
tological activity index (HAI) using the Ishak scoring
system [66].
Cytokine assay
Cytokines were assayed using quantitative ELISA plate
method: sIL-2Ra, IL-8, sTNFR-II and sFas using kits
provided by Quantikine (R&D Systems, Inc.614 McKinly
Place N.E. MN 55413, USA).
Statistical analysis
The SPSS software package (version 15) was used. Mean
± SD (standard deviation) were computed for the quan-
titative data. The non-parametric t-test equivalent
(Mann-Whitney test) and the non-parametric ANOVA
(Kruskal-Wallis test) were used to compare means of,
respectively, two or more than two independent groups.
Fisher’s exact and chi-square tests were used to validate
the hypothesis of proportional independency. Correla-
tion analysis was used to detect the association between
quantitative data.
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